CDK4 and neoplasm: Although significant enrichment in TP53 mutations was found in tumor samples resistant to CDK4/6i, additional preclinical data showed that baseline sensitivity to CDK4/6i in vitro was similar in TP53 wild-type and TP53-mutant HR+ cell lines [134].